Blockchain Registration Transaction Record

Heidelberg Pharma AGM Approves All Proposals, Elects New Board Member

Heidelberg Pharma AG reports 98.67% approval at 2026 Annual General Meeting, elects Jack Yefei Ling to Supervisory Board, and advances ATAC technology for cancer therapies.

<p>This news matters because Heidelberg Pharma's unique ATAC technology, derived from a deadly mushroom toxin, represents a novel therapeutic approach for hard-to-treat cancers like multiple myeloma and Non-Hodgkin Lymphoma. The strong shareholder support and strategic board changes signal confidence in the company's direction, potentially accelerating the development of its pipeline. For patients and investors, this could mean faster progress toward new cancer treatments and increased value as the company advances its clinical programs.</p>